Jyong Biotech said Monday that it priced its initial public offering of about 2.7 million ordinary shares at $7.50 per share, for expected gross proceeds of about $20 million.
The shares have been approved for listing on the Nasdaq Global Market and are expected to start trading on Tuesday under the ticker symbol "MENS". The offering is expected to close on Wednesday.
The company, which specializes in the treatment of urinary system diseases, also granted the underwriters a 45-day option to buy up to an additional 400,000 shares to cover possible over-allotments.
Jyong said it plans to use the net proceeds to fund clinical trials, new drug applications, and for other general corporate purposes.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.